Back to Market返回行情

CBLL CeriBell, Inc.

USHealthcare
$19.56-0.41%ClosedMarket Cap: $742.2M

As of 2026-07-10 16:00

Why CBLL matters now

CeriBell, Inc. (CBLL) is a US stock in Healthcare. The latest InvestLog snapshot shows $19.56 with -0.41% on the session and $742.2M in market capitalization; recent performance reads 1-month +6.31% and YTD -17.78%.

The latest financial table shown here is Q1 2026, with revenue of $26.5M, net income of $-19.7M, and EPS of $-0.52. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -7.2%.

The latest indexable market news headline is "Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes" from GlobeNewsWire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $25.00; recent insider activity includes Taylor Joseph Michael filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

4.82

P/S

7.20

EV/EBITDA

-11.54

DCF Value

$-46.67

FCF Yield

-7.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

87.7%

Operating Margin

-68.3%

Net Margin

-63.5%

ROE

-38.2%

ROA

-33.9%

ROIC

-39.8%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$26.5M$-19.7M$-0.52
Q4 2025$24.8M$-13.5M$-0.36
FY 2025$89.1M$-53.4M$-1.46
Q3 2025$22.6M$-13.5M$-0.37

Analyst Ratings

Consensus

Buy

Target (Consensus)

$25.00

Target (Median)

$25.00

Target Range

$25.00 - $25.00

Strong Buy: 1Buy: 7Hold: 0Sell: 0Strong Sell: 0
Canaccord GenuityBuy
2026-05-12
BTIGBuy
2026-01-28
Canaccord GenuityBuy
2025-12-17
BTIGBuy
2025-12-15
JP MorganOverweight
2025-11-05

Trading Activity

Insider Trades

Taylor Joseph Michaeldirector
Sell2026-06-15
Chao Xingjuandirector, officer: President and CEO
Sell2026-06-10
Chao Xingjuandirector, officer: President and CEO
Sell2026-06-10
Chao Xingjuandirector, officer: President and CEO
Sell2026-06-10
Chao Xingjuandirector, officer: President and CEO
Sell2026-06-10

Company Info

Sector

Healthcare

Industry

Medical - Devices

Country

US

Exchange

Beta

0.84

CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.